# EDGAR Filing Document

**Accession Number:** 0001723464
**File Stem:** 0001139020-25-000253
**Filing Date:** 2025-8
**Character Count:** 21862
**Document Hash:** a749ad15ce9cb08c589ddc4f51f99f33
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001139020-25-000253.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0001139020-25-000253

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250811

**FILED AS OF DATE**: 20250811

**DATE AS OF CHANGE**: 20250811

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOHARVEST SCIENCES INC.
- **CENTRAL INDEX KEY:** 0001723464
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42389
- **FILM NUMBER:** 251202497

**BUSINESS ADDRESS:**
- **STREET 1:** 1140 - 625 HOWE STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 2T6
- **BUSINESS PHONE:** 6046221186

**MAIL ADDRESS:**
- **STREET 1:** 1140 - 625 HOWE STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 2T6

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CANNA-V-CELL SCIENCES INC.
- **DATE OF NAME CHANGE:** 20191008

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Midnight Star Ventures Corp.
- **DATE OF NAME CHANGE:** 20171121

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **August 2025**

Commission file number: **001-42389**

**BIOHARVEST SCIENCES INC.**

(Exact name of Registrant as specified in its charter)

**Not applicable**

(Translation of Registrant's name into English)

**1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

**SUBMITTED HEREWITH**

**Exhibits:**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Exhibit** | &nbsp;&nbsp;**Description** |
| &nbsp;&nbsp;[99.1](bhsc_ex991.htm) | &nbsp;&nbsp;News Release dated August 11, 2025 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;**BIOHARVEST SCIENCES INC.** |
|  | &nbsp;&nbsp;(Registrant) |
| &nbsp;&nbsp;Date: August 11, 2025 | &nbsp;&nbsp;*/s/ David Ryan* |
|  | &nbsp;&nbsp;Name: David Ryan |
|  | &nbsp;&nbsp;Title: Vice-President, Investor Relations & Secretary |

---

## Exhibit 99.1

**BioHarvest Sciences Reports Second Quarter 2025 Financial Results**

*Robust 41% Year-Over-Year Revenue Growth, Driven by Strong Core Capsule and New Product Sales*

**Rehovot, Israel – August 11, 2025** - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025.

**Second Quarter 2025 Highlights**

*All figures stated in this news release are in U.S. dollars unless stated otherwise.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Total revenues for the second quarter of 2025 increased 41% year-over-year to $8.5 million, in line with management guidance, with gross margins of 60% expanding by 800 basis points year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Total U.S. active VINIA® users now 65,000, with >$60 million of cumulative revenue realized since USA launch in May 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Business delivering balanced growth, with new products representing ~20% of growth and the core VINIA capsule business driving ~80% of growth.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Core capsule business grew by 28% with new products increasing by 100%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Secured a new Stage 1 CDMO contract to develop a plant-based fragrance compound, derived from a plant that is under significant threat due to over-harvesting and habitat loss.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Announced first CDMO project to reach Stage 2 with completion of Stage 1 development for the CDMO contract with a Nasdaq-listed pharmaceutical company with an approved drug, successfully validating the botanical synthesis platform for a variety of molecule types.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Launched VINIA® Daily Chews 2X Formula. This "first-of-its-kind" chew features 3rd party certification and is designed to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles.

**Subsequent 2025 Outlook**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Management expects third quarter 2025 revenues of at least $9.1 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Additional products and CDMO services to be launched in the second half of 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Expectations to reach adj. EBITDA breakeven in the fourth quarter of 2025

**Management Commentary**

Ilan Sobel, CEO of BioHarvest Sciences, said: "The second quarter of 2025 was another strong quarter of operational execution, as we achieved our revenue guidance and advanced toward our goal of adjusted EBITDA breakeven in Q4 of this year. Results were driven by a combination of continued growth in both our core VINIA® capsule business and in recently launched "VINIA Inside" portfolio products. In addition, our CDMO business unit continues to increase its contribution to revenue growth as we recognize the dollars related to key milestone achievements with our customers. Our CDMO pipeline remains robust with multiple potential customers that we expect could convert in the next 6-9 months."

------

Looking ahead to the second half of 2025, the Company will launch three growth initiatives:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.**'Health Pros' Professional Affiliate Program** – A new network of health practitioners, athletes, coaches and health influencers with significant social media followings aimed at expanding VINIA's reach and driving subscriber growth at lower acquisition costs, with a target of 300 of these "Health Pros" onboarded by year-end.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.**AI-Enabled CDMO Discovery Phase** – A new billable service combining proprietary AI in rare plant biology with scientific expertise to accelerate client projects from pipeline to Stage 1 project, expected to drive additional CDMO revenue.

Management reiterates its focus on profitable growth and category-defining innovation, positioning botanical synthesis as a commercial engine for high-value plant-based compounds.

**Second Quarter 2025 Financial Results**

*All figures stated in this news release are in U.S. dollars unless stated otherwise.*

Revenues for the second quarter of 2025 increased 41% to $8.5 million - in line with management's revenue guidance - as compared to $6.0 million in the second quarter of 2024. The increase was a result of the continued success of the Company's VINIA® family of products.

Gross profit increased 65% to $5.1 million, or 60% of total revenue, in the second quarter of 2025, as compared to $3.1 million, or 52% of total revenue, in the same year-ago quarter. The increase in gross margin was primarily attributable to the benefits of increased manufacturing scale and improved manufacturing yields.

Total operating expenses for the second quarter totaled $6.9 million, as compared to $4.8 million in the same year-ago quarter. The increase in operating expenses was primarily due to increased marketing spend and the development of the health pro affiliates program to support future revenue growth - and higher expenses from the CDMO services division. General and administrative expenses increased 61% year-over-year due to one-time costs associated with our NASDAQ corporate compliance upgrade.

Net loss for the second quarter of 2025 totaled $4.0 million, or $0.24 per basic and diluted share, as compared to a net loss of $0.7 million, or $0.04 per basic and diluted share, in the same year-ago quarter. Q2 2025 increase in net loss vs PY was primarily due to non-cash finance expenses associated with exchange rate impact.

Adjusted EBITDA loss - a non-IFRS measure - totaled $1.3 million in the second quarter of 2025, as compared to an adjusted EBITDA loss of $1.2 million in the same year-ago quarter.

Cash and cash equivalents as of June 30, 2025, totaled $3.7 million, as compared to $2.4 million as of December 31, 2024.

------

**Second Quarter 2025 Results Conference Call**

Management will host an investor conference call and webcast at 8:00 a.m. Eastern time today to discuss the Company's second quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:

Date: Monday, August 11, 2025

Time: 8:00 a.m. Eastern time

U.S./Canada Dial-in: 1-877-300-8521

International Dial-in: 1-412-317-6026

Conference ID: 10199237

Webcast: BHST Q2 2025 Earnings Conference Call

Please dial in at least 10 minutes before the start of the call to ensure timely participation.

A telephone playback of the call will be available through Monday, August 25, 2025. To listen, call 1-844-512-2921 within the United States and Canada or 1-412-317-6671 when calling internationally, using replay pin number 10199237. A webcast replay will also be available at the webcast link above.

**About BioHarvest Sciences Inc.**

BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

**Use of Non-IFRS Financial Measures**

This press release includes the following non-IFRS measure - Adjusted EBITDA, which is not a measure of financial performance under IFRS and should not be considered as an alternative to net income as a measure of financial performance. Adjusted EBITDA represents net income (loss) before interest, taxes, depreciation and amortization adjusted for stock-based compensation and fair value adjustment of convertible loan and or warrants as well as issuance of warrants. The company believes this non-IFRS measure, when considered together with the corresponding IFRS measures, provides useful information to investors and management regarding financial and business trends relating to the company's results of operations. However, this non-IFRS measure has significant limitations in that it does not reflect all the costs and other items associated with the operation of the company's business as determined in accordance with IFRS. In addition, the company's non-IFRS measures may be calculated differently and are therefore not comparable to similar measures by other companies. Therefore, investors should consider non-IFRS measures in addition to, and not as a substitute for, or superior to, measures of financial performance in accordance with IFRS. A reconciliation of Adjusted EBITDA to net income, its corresponding IFRS measure, is shown below.

------

**IFRS NET INCOME (LOSS) TO ADJUSTED EBITDA RECONCILIATION**

(Unaudited)

(U.S dollars in thousands)

---

| | | |
|:---|:---|:---|
|  | **Three-month period ended June 30,**  | **Three-month period ended June 30,**  |
|  | **2025** | **2024** |
| Net (loss) | **($4080)** | **($687)** |
| Depreciation and Amortization (\*) | **407** | **352** |
| Taxes | **39** | **-** |
| Interest, net & Finance Charges | **638** | **53** |
| Fair Value adjustment of derivative liability –Convertible loan (\*) | **-** | **(1411)** |
| Warrants Issuance (\*) | **-** | **247** |
| Share Based Payment (\*) | **184** | **197** |
| Exchange rates impact and interest over leases (IFRS 16) (\*) | **1290** | **-** |
| Other exchange rate impact  | **267** | **-** |
| Adjusted EBITDA (Non-IFRS) | **($1255)** | **($1249)** |

---

(\*) Non cash items

**Forward-Looking Statements**

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. Readers are cautioned that future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. Launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is never an assurance that any product set will successfully disrupt established product categories. There is no assurance that the Company will maintain or improve current financial performance, as revenues and margins are dependent on a combination of factors such as supply chain efficiencies, input cost stability, marketing efficiencies and uncertain consumer preferences. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

**BioHarvest Corporate Contact:**

Dave Ryan, VP Investor Relations

+1 (604) 622-1186

info@bioharvest.com

**Investor Relations Contact:**

Lucas A. Zimmerman

Managing Director

MZ Group - MZ North America

+1 (949) 259-4987

BHST@mzgroup.us

------

**BioHarvest Sciences Inc. Consolidated Statements of Financial Position**

**U.S. dollars in thousands**

---

| | | |
|:---|:---|:---|
|  | **As at June 30,**<br> **2025** | &nbsp;&nbsp;**As at December**<br> **31, 2024** |
| **Assets** |  |  |
| **Current assets** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | **$3727** | $2390 |
| &nbsp;&nbsp;&nbsp;Trade accounts receivable | **1614** | 1116 |
| &nbsp;&nbsp;&nbsp;Other accounts receivable | **858** | 695 |
| &nbsp;&nbsp;&nbsp;Inventory | **4127** | 3655 |
| **Total current assets** | **10326** | 7856 |
| **Non-current** |  |  |
| &nbsp;&nbsp;&nbsp;Restricted cash | **397** | 371 |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | **8232** | 7750 |
| &nbsp;&nbsp;&nbsp;Right-of-use assets, net | **8843** | 9024 |
| **Total non-current assets** | **17472** | 17145 |
| **Total assets** | **$27798** | $25001 |
| **Liabilities** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Trade accounts payable | **$3421** | $3525 |
| &nbsp;&nbsp;&nbsp;Other accounts payable | **4503** | 3609 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | **990** | 906 |
| &nbsp;&nbsp;&nbsp;Lease liabilities | **1454** | 772 |
| &nbsp;&nbsp;&nbsp;Loans | **4722** | 3905 |
| &nbsp;&nbsp;&nbsp;Liability for Agricultural Research Organization | **1552** | 1140 |
| &nbsp;&nbsp;&nbsp;Accrued liabilities | **463** | 401 |
| **Total current liabilities** | **17105** | 14258 |
| **Non-current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Lease liability | **9654** | 9141 |
| &nbsp;&nbsp;&nbsp;Loans | **5262** | - |
| &nbsp;&nbsp;&nbsp;Liability to Agricultural Research Organization | **-** | 272 |
| **Total non-current liabilities** | **14916** | 9413 |
| **Shareholders' equity (deficit)** |  |  |
| &nbsp;&nbsp;&nbsp;Share capital and contributed surplus | **98613** | 97748 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | **(102836)** | (96418) |
| **Total Shareholders' equity (deficit)** | **(4223)** | 1330 |
| **Total liabilities and shareholders' equity (deficit)** | **$27798** | $25001 |

---

------

**BioHarvest Sciences Inc. Consolidated Statements of Loss and Other Comprehensive Loss**

**U.S. dollars in thousands, except per share data**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three-months period**<br> **ended June 30,** | **Three-months period**<br> **ended June 30,** | **Six-months period**<br> **ended June 30,** | **Six-months period**<br> **ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenues | **$8515** | $6027 | **$16375** | $11371 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of revenues | **3429** | 2925 | **6694** | 5266 |
| **Gross profit** | **5086** | 3102 | **9681** | 6105 |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | **1337** | 1088 | **2582** | 2122 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | **3987** | 2812 | **7668** | 5376 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | **1577** | 978 | **2965** | 1807 |
| **Total operating expenses** | **(6901)** | (4878) | **(13215)** | (9305) |
| **Operating loss** | **(1815)** | (1776) | **(3534)** | (3200) |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance income | **-** | (1467) | **-** | (49) |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance expenses | **2226** | 378 | **2807** | 4117 |
| **Net loss before tax** | **(4041)** | (687) | **(6341)** | (7268) |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes on income | **39** | - | **77** | - |
| **Net loss and comprehensive loss** | **$(4080)** | $(687) | **$(6418)** | $(7268) |
| Basic and diluted loss per share | (0.24) | (0.04) | (0.37) | (0.48) |

---

------

**BioHarvest Sciences Inc. Consolidated Statements of Cash Flows**

**U.S. dollars in thousands**

---

| | | |
|:---|:---|:---|
|  | **Six-months period**<br> **ended June 30,** | **Six-months period**<br> **ended June 30,** |
|  | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | **$(6418)** | $(7268) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and Amortization | **806** | 559 |
| &nbsp;&nbsp;&nbsp;Fair value adjustments of Convertible loans | **-** | 3453 |
| &nbsp;&nbsp;&nbsp;Fair value adjustments of derivative liability - Warrants | **-** | 408 |
| &nbsp;&nbsp;&nbsp;Interest over Agricultural Research Organization liability | **139** | 187 |
| &nbsp;&nbsp;&nbsp;Finance expense (income), net | **1920** | (13) |
| &nbsp;&nbsp;&nbsp;Share based compensation | **316** | 328 |
| **Changes in operations assets and liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Change in trade accounts receivable  | **(498)** | (97) |
| &nbsp;&nbsp;&nbsp;Change in other accounts receivable  | **(163)** | (191) |
| &nbsp;&nbsp;&nbsp;Change in inventory | **(472)** | (102) |
| &nbsp;&nbsp;&nbsp;Changes in trade accounts payable, other accounts payable and accrued liabilities | **1402** | (\*) 241 |
| &nbsp;&nbsp;&nbsp;Changes in deferred revenue | **85** | (\*) (3) |
| **Cash used in operations** | **(2883)** | (2498) |
| &nbsp;&nbsp;&nbsp;Interest paid | **-** | (38) |
| **Net cash used in operating activities** | **(2883)** | (2536) |
| **Cash flow from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Purchase of property and equipment | **(1276)** | (1930) |
| &nbsp;&nbsp;&nbsp;Deposit of restricted cash for bank guarantee, net of drawing | **4** | (225) |
| **Net cash used in investing activities** | **(1272)** | (2155) |
| **Cash flow from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Repayments of lease liabilities | **(477)** | (248) |
| &nbsp;&nbsp;&nbsp;Proceeds from loans, net of repayments | **5985** | - |
| &nbsp;&nbsp;&nbsp;Net proceeds from issuance of units of securities | **-** | 4330 |
| &nbsp;&nbsp;&nbsp;Exercise of options and warrants by employees and consultants | **-** | 408 |
| **Net cash provided by financing activities** | **5508** | 4490 |
| &nbsp;&nbsp;&nbsp;Exchange rate differences on cash and cash equivalents | **(16)** | 14 |
| &nbsp;&nbsp;&nbsp;Increase (Decrease) in cash and cash equivalents | **1353** | (201) |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents at the beginning of the period | **2390** | 5355 |
| **Cash and cash equivalents at the end of the period** | **$3727** | $5168 |
| **Significant non-cash transactions:** |  |  |
| &nbsp;&nbsp;&nbsp;Conversion of Convertible loans into shares | - | 20527 |
| &nbsp;&nbsp;&nbsp;Reclassification of warrants as an equity instrument | - | 934 |
| &nbsp;&nbsp;&nbsp;Purchase of property in installment agreement | - | 1995 |
| &nbsp;&nbsp;&nbsp;Recognition of right-of-use assets and lease liabilities | 399 | 8648 |

---